Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Oberotatug Ravtansine in Solid Tumor report and make more profitable business decisions.

This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Oberotatug Ravtansine in Solid Tumor Drug Details:

Oberotatug ravtansine (OBT-076) is under development for the treatment of solid tumor, her2 negative breast cancer, a type of non-Hodgkin lymphoma (NHL),  gastric cancer, endometrial cancer, non-small cell lung (NSCLC) cancer, and ovarian cancer and bladder cancers. It is administered through intravenous route as a solution. It is an antibody-drug conjugate (ADC) composed of fully humanized IgG1 monoclonal antibody conjugated to a potent cytotoxic maytansin toxin through a cleavable linker. ADC acts by targeting a type I transmembrane glycoprotein and a C-type lectin receptor Ly75/ CD205. It is being developed based on Oxford Genome Anatomy Project (OGAP) technology.It was also pancreatic cancer, triple negative breast cancer and diffuse large B-cell lymphoma (DLBCL) and adenoid cystic carcinoma (ACC) of the head and neck.

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.

The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Scope of Report

  • Drug Details: Drug name, Drug type, Intervention type
  • Administration Pathway
  • Therapeutic Areas
  • Key Manufacturers
  • Drug Development Status

Reasons to buy

  • Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
  • Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
  • Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
  • Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.

What our clients have to say

More Reports

View More Reports